PREDICTIVE VALUES OF PROCALCITONIN FOR SECONDARY BACTERIAL INFECTIONS IN PATIENTS WITH COVID-19
Keywords:
Keywords: SARS-CoV-2, pneumonia, C-reactive protein, procalcitonin, cytokines, biomarkers, prognosis.Abstract
ANNOTATION. This article highlights the importance of C-reactive protein
(CRP) and procalcitonin (PCT), and cytokines in determining the prognosis of SARS-
CoV-2-associated pneumonia. The article discusses the methods used to measure these
biomarkers and the results of studies that have investigated their use in predicting the
severity and outcome of SARS-CoV-2-associated pneumonia. The article concludes
with a discussion of the implications of these findings and suggestions for future
research.
References
References:
1. Arsenault, C., Gage, A., Kim, M.K. et al. COVID-19 and resilience of healthcare
systems in ten countries. Nat Med 28, 1314–1324 (2022).
2. Oblokulov, A.R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an
indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for
Cell Biology, 5220-5224.
3. Scaglioni V., Soriano E.R. Are super antigens the cause of cytokine storm and viral
sepsis in severe COVID-19? Observations and hypothesis // Scand. J. Immunology
–2020. –Vol. 92, no. 6. – P. 1–5.
4. Oblokulov, A. R., Niyozov, G.E. (2020) Clinical and epidemiological
characteristics of patients with COVID-19. International Journal of
Pharmaceutical Research; 12(4):3749-3752.
5. Gorbalenya A.E., et al. The species Severe acute res piratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol.
–2020. –Vol. 5, no. 4. –P. 536–544.
6. Encyclopaedia Britannica, Inc. – URL: https://www.britannica.com (date of
viewing: 12.01.2021).
7. Mahendra M, Nuchin A, Kumar R, et al. (2021) Predictors of mortality in patients
with severe COVID-19 pneumonia—a retrospective study. Adv Respir Med
89:135–144.
8. Bosch B.J., et al. The coronavirus spike protein is a class I virus fusion protein:
structural and functional characterization of the fusion core complex // J. Virol. –
2003. –Vol. 77, no. 16. –P. 8801–8811.
9. Lanzavecchia A. Antigen-specific interaction between T and B cells // Nature. –
1985. – Vol. 314, no. 11. – P. 537–539.
10. Scaglioni V., Soriano E.R. Are superantigens the cause of cytokine storm and viral
sepsis in severe COVID-19? Observations and hypothesis // Scand. J. Immunol. –
2020. – Vol. 92, no. 6. – P. 1–5.
11. Gorbalenya A.E., et al. The species Severe acute res piratory syndrome-related
coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 // Nat. Microbiol.
– 2020. – Vol. 5, no. 4. – P. 536–544.
12. Encyclopaedia Britannica, Inc. – URL: https:// www.britannica.com (date of
viewing: 12.01.2021).
13. Schoeman, D. Coronavirus envelope protein: current knowledge // Virol. J. – 2019.
– Vol. 16, no. 1. – P. 69.
14. Williams EJ et al. (2020). Routine measurement of serum procalcitonin allows
antibiotics to be safely with held in patients admitted to hospital with SARS-CoV-
2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
15. Oblokulov A.R., Kholov U.A., Niyozov G.E., Khusenova Z.Z., Ergashov M.M.
(2021) Extrapulmonal manifestations of COVID – 19 // “Infection, immunity and
pharmacology –scientific and practical journal - №1/2021. P. - 62-66.
16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-
19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;
395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
17. Облокулов А.Р., Хусенова З.З., Эргашов М.М. (2021) Значение Уровня
Прокальцитонина при назначении и мониторинга антибактериальной терапии
пациентов с COVID – 19 // Журнал гепато – гастроэнтерологических
исследований. Том №1, Специалый выпуск. Cт. -115-117
18. Nahum J, et al. Venous thrombosis among critically ill patients with coronavirus
disease 2019 (COVID-19) JAMA Netw. Open. 2020;3: e2010478. doi:
10.1001/jamanetworkopen.2020.10478.
19. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in
patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. 2020;
18:1421–1424. doi: 10.1111/jth.14830.
20. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395:1054–
1062. doi: 10.1016/S0140-6736(20)30566-3.
21. Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N.
Engl. J. Med. 2020; 382:1708–1720. doi: 10.1056/NEJMoa2002032.
22. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan
L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
doi: 10.1016/S0140-6736(20)30566-3.
23. Wesley H. Self and others, Procalcitonin as a Marker of Etiology in Adults
Hospitalized with Community-Acquired Pneumonia, Clinical Infectious Diseases,
Volume 65, Issue 2, 15 July 2017, Pages 183–190.
24. Clyne B, Olshaker JS (1999) The C-reactive protein. J Emerg Med 17:1019–1025.
25. Авдеева М.Г., Облокулов А.Р., Эргашов М.М. (2022) Прокальцитонин как
предиктор антибактериальной терапии при Covid-19 // Новый День в
Медицине Том 2 (40) 2022. Ст. -323-327.
26. Williams EJ et al. (2020) Routine measurement of serum procalcitonin allows
antibiotics to be safely with held in patients admitted to hospital with SARS-CoV-
2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
27. Ergashov M.M. (2023) The importance of C-reactive protein, procalcitonin, and
cytokines in determining the prospect of SARS-COV-2-associated pneumonia //
Galaxy International Interdisciplinary Research Journal (GIIRJ) ISSN (E): 2347-
6915. Vol. 11, Issue 04, April. P.-480-483.
28. Rothe K, Feihl S, Schneider J, et al. (2021) Rates of bacterial co-infections and
antimicrobial use in COVID-19 patients: a retrospective cohort study in light of
antibiotic stewardship. Eur J Clin Microbiol Infect Dis 40:859–869
